02 May, EOD - Indian

SENSEX 80501.99 (0.32)

Nifty 50 24346.7 (0.05)

Nifty Bank 55115.35 (0.05)

Nifty IT 35891.85 (0.27)

Nifty Midcap 100 53705.1 (-0.78)

Nifty Next 50 64429.75 (-0.12)

Nifty Pharma 21627.45 (-0.67)

Nifty Smallcap 100 16441.8 (-0.04)

02 May, EOD - Global

NIKKEI 225 36830.69 (1.04)

HANG SENG 22504.68 (1.74)

S&P 5722.5 (1.55)

LOGIN HERE

companylogoGufic BioSciences Ltd

You are Here : Home > Markets > CompanyInformation > Company Background
BSE Code : 509079 | NSE Symbol : GUFICBIO | ISIN : INE742B01025 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |


Chairman's Speech

"As we look back on our legacy, we are inspired to continue pushing the boundaries of what is possible in healthcare."

Dear Shareholders and Stakeholders,

As we commemorate around 24 years of Gufic's journey, we stand on the strong foundation of our core principles: incubating life, uplifting life and protecting life. These are not just ideals; they are the guiding forces behind every decision we make and every innovation we pursue. In an ever-evolving healthcare landscape, our commitment to these principles remains as strong as ever, driving us towards a future of continued growth and impact.

Over the past two decades, Gufic has grown from a modest pharmaceutical venture into a recognized leader in the industry. Our journey has been marked by numerous milestones, from pioneering life-saving therapies to expanding our footprint across global markets. Each of these achievements is a testament to the dedication of our teams and the trust placed in us by our stakeholders. As we look back on our legacy, we are inspired to continue pushing the boundaries of what is possible in healthcare.

Our Four Pillars: Driving Innovation and Excellence

Our business is built around four primary pillars, each representing a key area where we see tremendous potential to make a meaningful impact on global health: Critical Care (Life-Saving Injectables), Assisted Reproductive Technologies (ART), Toxins and Science-Based Nutraceuticals. These pillars are not just business segments; they embody our mission to address some of the most pressing medical challenges of our time.

Pillar One: Critical Care (Life-Saving Injectables)

India's healthcare infrastructure is expanding rapidly, with a nationwide effort to add 2.4 million hospital beds. As access to life-saving antibacterial improves, so does the risk of antimicrobial resistance (AMR).At Gufic, we are addressing this challenge head-on with a two-pronged strategy. We are conducting large-scale scientific engagements to promote the correct use of these critical medicines while also focusing on the development of novel antifungals and first-in-class antibiotics. Our goal is clear: to improve patient outcomes and protect lives by ensuring that the medical community has access to safe and effective anti-infective therapies.

Pillar Two: Assisted Reproductive Technologies (ART)

Infertility is a global issue that affects millions, and India bears a significant portion of this burden. With approximately 15 to 20 million couples in India struggling with infertility, the demand for effective and accessible treatments has never been greater. Gufic is committed to being a trusted partner in the field of ART, providing critical hormonal and support therapies that enhance the success rates of IVF cycles. We are also investing in cutting-edge research to develop recombinant products and innovative treatments for conditions such as recurrent implantation failure and endometriosis. Through these efforts, we hope to bring the joy of parenthood to countless families, fulfilling our mission of incubating life.

Pillar Three: Toxins

Botulinum toxin is a remarkable natural substance with the power to transform lives. While it is widely known for its cosmetic applications, it also has significant therapeutic potential in treating severe neurological conditions that impair quality of life. In India, many of these conditions remain under-treated, and it is our aim to change that. Through clinical trials, training programs, and scientific engagements, Gufic is working to democratize access to botulinum toxin, ensuring that more patients can benefit from its life-enhancing properties.

Pillar Four: Science-Based Nutraceuticals

Gufic has long been a pioneer in the development of Boswellia serrata-based nutraceuticals, which have proven effective in managing various types of pain. Our commitment to scientific research continues to drive the creation of new products that harness the therapeutic potential of natural ingredients. From bronchial asthma to osteo-muscular pain, we are dedicated to providing science-backed solutions that address widespread medical conditions and improve the quality of life for our patients.

Sustainability and Social Responsibility

As we innovate, we also recognize our responsibility towards the environment and society. Sustainability is woven into the fabric of our operations, from sourcing raw materials responsibly to minimizing our carbon footprint through energy-efficient practices. Our Corporate Social Responsibility (CSR) initiatives are focused on improving healthcare access in underserved communities, promoting education and supporting environmental conservation efforts. At Gufic, we believe that doing well and doing good are not mutually exclusive as they are integral to our long-term success.

Strategic Vision and Future Growth

Looking ahead, we are committed to strengthening our core pillars while exploring new opportunities for growth. Our investment in state-of-the-art manufacturing facilities, such as the new plant in Indore, positions us to meet increasing global demand while maintaining the highest standards of quality. We are also exploring strategic partnerships and collaborations that align with our mission and expand our reach into new markets.

Acknowledgements and a Shared Future

None of our achievements would have been possible without the unwavering support of our shareholders, employees, partners, and all stakeholders. Your trust and dedication have been the cornerstones of our success. As we move forward, we are committed to delivering continued value, driving innovation, and making a positive impact on society. Together, we will build on our legacy to create a healthier, brighter future for all.

Thank you for being a part of Gufic's journey.

Yours faithfully,
For Gufic Biosciences Limited
Jayesh P. Choksi
Chairman & Managing Director

   

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +